Aperya

We’re thrilled to announce that Aperya has been selected as one of the 5 featured projects on this year’s IVA 100 List by the Royal Swedish Academy of Engineering Sciences! 🎉 Each year, IVA highlights groundbreaking research projects with strong commercialization potential. Earlier today, Niclas Roxhed joined IVA HQ to discuss the future of skincare and how Aperya is set to play a key role in transforming it. Exciting times ahead! 🚀

KTH spinoff Aperya is developing new needle technology that makes skin cream and dermatology more effective, based on research by Niclas Roxhed and Theocharis Iordanidis. The microspheres resemble tiny spikes on a microscopic sphere. The aim of the technology is to improve the penetration of drugs and skin creams, potentially allowing ingredients in cosmetics and medicines to penetrate the skin up to 100 times more effectively. Third co-founder, KTH Master’s student William Ferreira Andrén recently finished his degree project at Stanford. Aperya is one of the teams in KTH Innovation Launch, a program for promising startup projects from KTH. Apply by 13 November at kth.se/launch! #KTHInnovation #ItAllStartsHere

New Name! - Previously Morningstar Therapeutics Check out our website! Aperya.com

At Morningstar Therapeutics, we’re focused on solving a key challenge in dermatology - inefficient delivery of active ingredients in creams -> Our platform boosts key ingredient delivery by up to 100X, opening up a new dermatological category within longevity and health. 🧬 A huge thanks to Bryan Johnson for hosting the Don't Die SF Summit, a great opportunity to discuss, and get a peak, of the future of health and longevity!

Thank you Stockholm Science City for highlighting us in your latest news letter! 🙌 We are very happy of the support Niclas Roxhed has received from the LEO Foundation // LEO Fondet! 🚀 #Biologics #Cosmetics #Skin #Dermatology #mRNA #Exosomes

Exciting news from KTH Innovation spin-off Morningstar Therapeutics! Founder Niclas Roxhed has just secured a 6.1 million Swedish Crown research grant from the LEO Foundation // LEO Fondet. This funding will advance the development of their rolling microneedle spheres – here used to deliver nucleic acids to reprogram skin cells and treating atopic eczema.   ”Very exciting times ahead for us to showcase the capabilities of our technology. Collaboration with Samir EL Andaloussi at Karolinska Institutet, a pioneer in biologic therapeutics, represents the potential of combining innovations to make biologic therapies for skin easily available to everyone!” says CTO Theocharis Iordanidis, a PhD student at KTH.   Morningstar Therapeutics is one of the teams in the KTH Innovation pre-incubator program. This spring, CEO William Ferreira Andrén will spend 4 months at Stanford University completing his Master’s Thesis in Medical Biotechnology at KTH, and networking with venture capitalists and business angels in Silicon Valley. William’s research will focus on optimizing the application of their microneedle spheres in creams, a crucial step for their initial products currently in development. #KTHInnovation #ItAllStartsHere

🌟 We are delighted to share that our co-founder, Niclas Roxhed, in collaboration with Samir EL Andaloussi's lab at Karolinska Institutet, has been awarded a grant of 6.1 MSEK from the LEO Foundation. This grant supports research aimed at treating atopic dermatitis, in a model, using our innovative rolling microneedle spheres to deliver nucleic acids topically, reprogramming skin cells. 🚀 This development marks the start of an exciting journey for our us as we venture into the realm of biologics within topical skin creams, pioneering a new category of treatments. We look forward to the transformative potential this project holds for skin health. 🌎 Join us and let’s build the future of dermatology together! Niclas Roxhed Theocharis Iordanidis William Ferreira Andrén #DrugDelivery #Innovation #SkinHealth #Biologics #Dermatology

We are excited to be a part of this innovative community alongside other groundbreaking companies supported by KTH Innovation. Morningstar Therapeutics is proud to contribute to a future where drug delivery is pain-free, enhancing patient care and experience. 🌍 Big cheers to all other teams making strides in healthcare technology! 🌟 William Ferreira Andrén Theocharis Iordanidis Niclas Roxhed #Innovation #HealthTech #KTHInnovation #MorningstarTherapeutics #PainFreeFuture

Morningstar Therapeutics is at Techarenan for two action-packed days, February 22-23, 2024, at Friends Arena in Stockholm. We're thrilled to connect with innovators and thought leaders in the tech space. Want to chat about groundbreaking therapies and our latest developments? We’d love to meet you. Drop us a message here on LinkedIn or find us on the TechArena platform. Don't miss out on the opportunity to engage with our team members Theocharis Iordanidis, William Ferreira Andrén, and Niclas Roxhed, who are eager to share insights and explore collaborations. Let's shape the future together! See you at #TechArena2024 🚀

Come meet us at Collide, February 13th, at KTH Innovation! 🙌 We will be there from 17:00 to 19:00! See you there! 👋